Advanced Accelerator Applications
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$96.8M
Doctors Paid
1,188
Transactions
2,906
2024 Total
$63.9M
Payment Breakdown by Category
Research$2.4M (2.4%)
Consulting$486,299 (0.5%)
Travel$83,417 (0.1%)
Food & Beverage$61,613 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93.7M | 745 | 96.7% |
| Unspecified | $2.4M | 202 | 2.4% |
| Consulting Fee | $486,299 | 176 | 0.5% |
| Travel and Lodging | $83,417 | 191 | 0.1% |
| Honoraria | $78,667 | 26 | 0.1% |
| Grant | $64,750 | 12 | 0.1% |
| Food and Beverage | $61,613 | 1,473 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $10,800 | 5 | 0.0% |
| Education | $8,824 | 76 | 0.0% |
Payments by Type
General
$94.5M
2,704 transactions
Research
$2.4M
202 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | $860,396 | 0 | 2 |
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours | $534,333 | 1 | 77 |
| PROter study | $222,121 | 0 | 17 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | $148,876 | 0 | 2 |
| Netter 1 | $98,739 | 0 | 46 |
| Annexin-03 / Annexin-04 / Annexin-05 | $86,092 | 1 | 6 |
| DOSIMETRY GUIDED PRRT WITH 177LU-DOTATATE IN CHILDREN AND ADOLESCENTS | $69,725 | 0 | 1 |
| NEORAY | $66,427 | 0 | 3 |
| NeoRay | $61,435 | 0 | 2 |
| Annexin | $43,467 | 0 | 1 |
| NETTER-1 CLINICAL TRIAL | $42,214 | 0 | 14 |
| STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUTATHERA IN PATIENTS WITH GRADE 2 AND GRADE 3 ADVANCED | $32,520 | 0 | 5 |
| Somatostatin Receptor Expression in Poorly-differentiated neuroendocrine carcinomas of the GI Tract: analysis using Ga-dotatate PET scan | $24,799 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Manish Kohli, Md, MD | Hematology & Oncology | Salt Lake City, UT | $5,330 | $0 |
| Mrs. Tanya Dorff, M.d, M.D | Hematology & Oncology | Duarte, CA | $5,056 | $0 |
| William Oh, M.d, M.D | Medical Oncology | Greenwich, CT | $5,000 | $0 |
| Erin Cook Grady, Md, MD | Internal Medicine | Stanford, CA | $5,000 | $0 |
| Elward Crawford, Md, MD | Urology | San Diego, CA | $4,984 | $0 |
| Lauren Harshman, Md, MD | Medical Oncology | Boston, MA | $4,961 | $0 |
| Tomasz Beer, Md, MD | Medical Oncology | Portland, OR | $4,903 | $0 |
| Dr. Neeraj Agarwal, Md, MD | Internal Medicine | Salt Lake City, UT | $4,778 | $0 |
| Edwin Posadas, Md, MD | Hematology & Oncology | Burr Ridge, IL | $4,516 | $0 |
| Robert Mcdonald, Md, MD | Nuclear Medicine | Casa Grande, AZ | $4,485 | $0 |
| Dr. Jennifer Chan, M.d, M.D | Neuropathology | Boston, MA | $4,313 | $0 |
| Christopher Sweeney, M.d, M.D | Medical Oncology | Boston, MA | $4,125 | $0 |
| Dr. David Quinn, M.d, M.D | Medical Oncology | Los Angeles, CA | $4,046 | $0 |
| Dr. Dane Dickson, Md, MD | Hematology & Oncology | Rexburg, ID | $3,800 | $0 |
| Daniel Spratt, M.d, M.D | Radiation Oncology | Cleveland, OH | $3,480 | $0 |
| Dr. Jennifer Chan, Md, MD | Internal Medicine | Boston, MA | $3,425 | $0 |
| Michael Morris, Md, MD | Medical Oncology | New York, NY | $3,347 | $0 |
| Ms. Namrata Vijayvergia, M.d, M.D | Medical Oncology | Philadelphia, PA | $3,275 | $0 |
| Michael Soulen, Md, MD | Vascular & Interventional Radiology | Philadelphia, PA | $3,208 | $0 |
| Andrew Armstrong, Md, MD | Medical Oncology | Durham, NC | $3,144 | $0 |
| Shyam Srinivas | Nuclear Radiology | Stanford, CA | $3,125 | $0 |
| Maha Hussain, Mb,Chb, MB,CHB | Internal Medicine | Ann Arbor, MI | $3,000 | $0 |
| Dr. Lisa Bodei, Md, Phd, MD, PHD | Nuclear Imaging & Therapy | New York, NY | $2,943 | $0 |
| Dr. John Sheldon, Md, MD | Radiation Oncology | Northampton, MA | $2,820 | $0 |
| David Metz, Md, MD | Internal Medicine | Philadelphia, PA | $2,787 | $0 |
Ad
Top Products
- PLUVICTO $63.9M
- LUTATHERA $30.3M
Associated Products (5)
- LUTATHERA $50.0M
- LUTATHERA (lutetium LU 177 dotatate) $978,418
- LUTATHERA (lutetium Lu 177 dotatate) $137,684
- NETSPOT (kit for the preparation of gallium Ga 68 dotatate for injection) $96,528
- Lutathera $62,408
Payment Categories
- Food & Beverage $61,613
- Consulting $486,299
- Travel & Lodging $83,417
- Research $2.4M
About Advanced Accelerator Applications
Advanced Accelerator Applications has made $96.8M in payments to 1,188 healthcare providers, recorded across 2,906 transactions in the CMS Open Payments database. In 2024, the company paid $63.9M. The top product by payment volume is PLUVICTO ($63.9M).
Payments were distributed across 64 medical specialties. The top specialty by payment amount is Medical Oncology ($229,968 to 100 doctors).
Payment categories include: Food & Beverage ($61,613), Consulting ($486,299), Research ($2.4M), Travel & Lodging ($83,417).
Advanced Accelerator Applications is associated with 5 products in the CMS Open Payments database, including LUTATHERA, LUTATHERA (lutetium LU 177 dotatate), and LUTATHERA (lutetium Lu 177 dotatate).